Lonza Group AG

Lonza Group AG is a leading global contract development and manufacturing organization (CDMO) specializing in the healthcare sector. Established in 1897 and headquartered in Basel, Switzerland, the company partners with pharmaceutical, biotechnology, and specialty ingredients industries to transform medical innovations into commercial therapies. Lonza’s operations are organized through three synergistic business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, covering the spectrum from early-stage development to large-scale manufacturing of advanced drugs. The company is recognized for its expertise in producing monoclonal antibodies, advanced cell and gene therapies, highly potent active pharmaceutical ingredients (APIs), and bioconjugates. Lonza maintains a significant international presence, operating over 30 sites worldwide and employing around 18,000 people. The group plays a vital role in accelerating pharmaceutical breakthroughs, addressing complex manufacturing needs, and supporting the global healthcare ecosystem by ensuring the availability of life-saving and life-enhancing treatments.